Literature DB >> 1701780

Selective in vivo inhibition of T cell activation by class II MHC-binding peptides administered in soluble form.

S Muller1, L Adorini, A Juretic, Z A Nagy.   

Abstract

A synthetic peptide corresponding to residues 53-61 of hen egg white lysozyme, as well as its N-succinyl C-amide, inhibit in vivo priming for T cell responses when administered in soluble form, in osmotic minipumps implanted s.c., 1 day before immunization. The inhibition exhibits MHC selectivity that corresponds to the binding specificity of these peptides for class II MHC molecules in vitro. Approximately fourfold higher doses of soluble competitor are required than of competitor in CFA-depot, in order to achieve comparable levels of inhibition. The inhibition of priming to a nonimmunodominant T cell determinant requires lower doses of soluble competitor than the suppression of priming to a dominant T cell determinant. The soluble competitors do not appear to induce class II MHC-restricted T cell response against themselves.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701780

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  A role for major histocompatibility complex-binding peptides in the immunotherapy of autoimmune disease.

Authors:  D C Wraith; D E Smilek
Journal:  Springer Semin Immunopathol       Date:  1992

Review 2.  Approaches toward peptide-based immunotherapy of autoimmune diseases.

Authors:  L Adorini; J C Guéry; S Trembleau
Journal:  Springer Semin Immunopathol       Date:  1992

3.  Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination.

Authors:  Li Li; Zuoan Yi; Bo Wang; Roland Tisch
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422

4.  Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex class II-restricted T cells.

Authors:  L Adorini; J Moreno; F Momburg; G J Hämmerling; J C Guéry; A Valli; S Fuchs
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

5.  Unresponsiveness to a self-peptide of mouse lysozyme owing to hindrance of T cell receptor-major histocompatibility complex/peptide interaction caused by flanking epitopic residues.

Authors:  K D Moudgil; I S Grewal; P E Jensen; E E Sercarz
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

6.  Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation.

Authors:  J C Guéry; A Sette; J Leighton; A Dragomir; L Adorini
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

7.  Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide.

Authors:  U Hurtenbach; E Lier; L Adorini; Z A Nagy
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

8.  Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone.

Authors:  M H Wauben; C J Boog; R van der Zee; I Joosten; A Schlief; W van Eden
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

9.  Selective immunosuppression by administration of major histocompatibility complex class II-binding peptides. II. Preventive inhibition of primary and secondary in vivo antibody responses.

Authors:  J C Guéry; M Neagu; G Rodriguez-Tarduchy; L Adorini
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.